23andMe Holding Co.
NASDAQ:ME
Intrinsic Value
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. [ Read More ]
The intrinsic value of one ME stock under the Base Case scenario is 2.4192 USD. Compared to the current market price of 0.4671 USD, 23andMe Holding Co. is Undervalued by 81%.
Valuation Backtest
23andMe Holding Co.
Run backtest to discover the historical profit from buying and selling ME stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
23andMe Holding Co.
Current Assets | 298m |
Cash & Short-Term Investments | 256.4m |
Receivables | 1.5m |
Other Current Assets | 40.1m |
Non-Current Assets | 503.2m |
PP&E | 85.4m |
Intangibles | 408.5m |
Other Non-Current Assets | 9.3m |
Current Liabilities | 101.6m |
Accounts Payable | 8.5m |
Accrued Liabilities | 51.9m |
Other Current Liabilities | 41.2m |
Non-Current Liabilities | 74.4m |
Other Non-Current Liabilities | 74.4m |
Earnings Waterfall
23andMe Holding Co.
Revenue
|
248m
USD
|
Cost of Revenue
|
-135.7m
USD
|
Gross Profit
|
112.3m
USD
|
Operating Expenses
|
-444m
USD
|
Operating Income
|
-331.7m
USD
|
Other Expenses
|
-190.3m
USD
|
Net Income
|
-522m
USD
|
Free Cash Flow Analysis
23andMe Holding Co.
ME Profitability Score
Profitability Due Diligence
23andMe Holding Co.'s profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
23andMe Holding Co.'s profitability score is 21/100. The higher the profitability score, the more profitable the company is.
ME Solvency Score
Solvency Due Diligence
23andMe Holding Co.'s solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
23andMe Holding Co.'s solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ME Price Targets Summary
23andMe Holding Co.
According to Wall Street analysts, the average 1-year price target for ME is 1.2597 USD with a low forecast of 0.4747 USD and a high forecast of 2.1 USD.
Ownership
ME Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ME Price
23andMe Holding Co.
Average Annual Return | -31% |
Standard Deviation of Annual Returns | 42.21% |
Max Drawdown | -98% |
Market Capitalization | 223.6m USD |
Shares Outstanding | 482 920 000 |
Percentage of Shares Shorted | 10.85% |
ME News
Last Important Events
23andMe Holding Co.
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
23andMe Holding Co.
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California. The company went IPO on 2020-10-06. The firm offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The firm operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one ME stock under the Base Case scenario is 2.4192 USD.
Compared to the current market price of 0.4671 USD, 23andMe Holding Co. is Undervalued by 81%.